In our latest Liberty Update, we highlight an eye-opening new study confirming how drug price controls…
CFIF on Twitter CFIF on YouTube
AEI's Michael Rosen: "Omicron Variant Sows Chaos but Doesn’t Move Needle on Patent Waiver Debate"

In our latest Liberty Update, we highlight an eye-opening new study confirming how drug price controls kill pharmaceutical investment and innovation at the worst possible time, when America and the entire world depend upon them more than ever.

In similar vein, American Enterprise Institute (AEI) Adjunct Fellow and healthcare expert Michael Rosen nicely illustrates how the omicron variant of Covid has paused the destructive global effort to suspend enforcement of patent rights belonging to lifesaving vaccine developers:

But the new omicron variant of the virus has intervened, shelving the planned WTO meeting and throwing into continued contrast the supposed haves and have-nots of vaccine protection...  But the EU has held firm in resisting the vaccine waiver, and rightly so."

Unfortunately…[more]

December 06, 2021 • 12:20 PM

Liberty Update

CFIFs latest news, commentary and alerts delivered to your inbox.
CFIF Submits Formal Comment on NIST Proposed Rule Regarding Bayh-Dole Act of 1980 Print
By CFIF Staff
Monday, April 12 2021

Last week, the Center for Indvidiual Freedom (CFIF) submitted a formal Comment with the U.S. Commerce Department's National Institute of Standards and Technology (NIST) on its Proposed Rule regarding the Bayh-Dole Act of 1980, which granted universities, nonprofit organizations and small business the right to patent and license inventions funded partly by federal funding. 

The Economist magazine called the Bayh-Dole Act "Possibly the most inspired piece of legislation to be enacted in America over the past half century," and rightfully so.  It unleashed a tidal wave of hundreds of thousands of patents issued to American universities and research institutes since then. 

On that basis, CFIF supports the Proposed Rule to the extent that it advances the provisions and intent of Bayh-Dole, with the caveat that insertion of the terms "exclusively" and "of the contractor" in the Proposed Rule's text may open the door for advocates of drug price controls to suggest that business decisions of pharmaceutical innovators regarding the pricing of commercial goods and services arising from the practical application of inventions may serve as one basis for exercising march-in rights.  Neither the text nor the intent of the Bayh-Dole Act allow that, as namesake Senators Bayh and Dole themselves pointed out in a joint statement to The Washington Post

On that basis we urge that the Proposed Rule omit those terms.  We must ensure that Bayh-Dole's four-decade legacy of incredible success continues, without the looming threat that activists may attempt to use it to impose destructive drug price controls on American consumers.

Read CFIF's comment here (PDF).

Quiz Question   
Which of the following is famously known as “a date which will live in infamy”?
More Questions
Notable Quote   
 
"As a member of Congress, Rep. Alexandria Ocasio-Cortez makes a whopping $174,000 annually, meaning that she individually earns more than twice the average U.S. household's income. Yet the progressive Democrat nonetheless thinks that working-class taxpayers should have to pay off her student loan debt.That's one of the main takeaways from Ocasio-Cortez's latest speech on the House floor. In the congresswoman…[more]
 
 
—Brad Polumbo, Freelance Writer
— Brad Polumbo, Freelance Writer
 
Liberty Poll   

In your Christmas shopping thus far, how are you faring?